Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 338 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast... June 11, 2019 En gran cantidad de casos el exito o examen experto os... August 21, 2023 How I Navigated Being a Young Mom During Cancer: A Survivor’s... February 15, 2023 ESMO World Congress on Gastrointestinal Cancer 2020 June 22, 2020 Load more HOT NEWS Rare Disease Day 2026: Advancing equity for people living with rare... When Natural Disasters Strike, This Program Helps Provide Relief To People... Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT... Feeding the Gut
